Research by Ershov et al
1 REIMAGINE 2 was a 68-week phase 3 trial evaluating the safety and efficacy of CagriSema in doses 2.4 mg/2.4 mg and 1 mg/1 mg once weekly versus semaglutide 2.4 mg, semaglutide 1 mg, cagrilintide 2.4 mg, and dose-matched placebo in 2,713 adults with T2D inadequately controlled with metformin with or without an SGLT2 inhibitor
Certificate access: A dated, lot-matched COA is non-negotiable
Regulation of senescence associated signaling mechanisms in chondrocytes for cartilage tissue regeneration
It measures decreases in hcg levels, which may indicate treatment outcomes, miscarriage, or natural resolution in certain conditions
George Ibrahim about the surge in peptide use for injury recovery, energy, weight loss, and more, plus why many peptides arent FDA-approved and have limited human data